Evgen Pharma PLC Notice of Results (8287A)
26 Mayo 2023 - 5:00AM
UK Regulatory
TIDMEVG
RNS Number : 8287A
Evgen Pharma PLC
26 May 2023
Evgen Pharma plc
("Evgen" or "the Company" or "the Group")
Notice of Full Year Results
26 May 2023 - Evgen Pharma plc (AIM: EVG), the clinical stage
drug development company developing sulforaphane-based medicines
for the treatment of multiple diseases, will report its full year
results for the financial year ended 31 March 2023 on Wednesday, 7
June 2023.
Enquiries:
Evgen Pharma plc Tel: +44 207 457 2020
Dr Huw Jones, CEO enquiries@evgen.com
Richard Moulson, CFO
FinnCap (Nominated Advisor and Tel: +44 20 7220 0500
Broker)
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane/Nigel Birks (ECM)
Instinctif Partners Tel: +44 207 457 2020
Melanie Toyne-Sewell / Rozi Morris Evgen@Instinctif.com
/ Adam Loudon
Notes to Editors
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases. The Company's core technology is Sulforadex(R),
a method for synthesising and stabilising the highly biologically
active compound sulforaphane and novel proprietary analogues based
on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of
synthetic sulforaphane and alpha-cyclodextrin and has undergone
clinical trials for oestrogen-positive (ER+) metastatic breast
cancer and recently a Phase 1b study of the Company's new enteric
coated tablet formulation. The FDA has granted Orphan Drug status
to SFX-01 in malignant glioma. SFX-01 will be investigated
initially in this indication as an investigator sponsored study in
the Netherlands.
The Company also has a wide number of collaborations with
leading academic centres in the UK, Europe and the US as part of
the continuing strategy to build the scientific data for the
compound. With respect to areas outside of oncology and
inflammation, Evgen signed an out-licensing deal with JuvLife, the
dietary products and functional foods division of Juvenescence Ltd,
for the development of a naturally-sourced sulforaphane nutritional
health supplement, stabilised using Evgen's Sulforadex(R)
technology. More recently Evgen completed an out-licensing
transaction with Stalica SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum
disorder. The deal, if successful, will generate milestone payments
of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and registered office at
Alderley Park, Cheshire. It is listed on AIM in London and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSEWSUMEDSELI
(END) Dow Jones Newswires
May 26, 2023 06:00 ET (10:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Evgen Pharma (LSE:EVG)
Gráfica de Acción Histórica
De May 2023 a May 2024